- Home
- SHEN vs XNCR Comparison
SHEN vs XNCR Comparison
Compare SHEN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHEN | XNCR |
|---|---|---|
| Founded | 1902 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 803.5M | 881.9M |
| IPO Year | 1994 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SHEN | XNCR |
|---|---|---|
| Price | $14.61 | $11.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $26.00 | $22.89 |
| AVG Volume (30 Days) | 222.2K | ★ 666.5K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $357,854,000.00 | $125,576,000.00 |
| Revenue This Year | $6.58 | N/A |
| Revenue Next Year | N/A | $6.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 9.08 | ★ 13.65 |
| 52 Week Low | $9.67 | $6.92 |
| 52 Week High | $15.92 | $18.69 |
Technical Indicators
Market Signals| Indicator | SHEN | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.24 | 45.33 |
| Support Level | $14.31 | $10.92 |
| Resistance Level | $15.86 | $12.87 |
| Average True Range (ATR) | 0.64 | 0.77 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 47.01 | 33.05 |
Price Performance
Historical ComparisonAbout SHEN Shenandoah Telecommunications Co
Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.